Global X - Genomics & Biotechnology ETF (GNOM) Fund Overview

Global X - Genomics & Biotechnology ETF (GNOM) Financial Services Profile

Global X Genomics & Biotechnology ETF (GNOM) provides targeted exposure to the genomics and biotechnology sectors by mirroring the Solactive Genomics Index. With a focus on innovation in healthcare, GNOM offers investors a way to participate in the potential growth of companies involved in gene editing, personalized medicine, and other biotechnological advancements within the global asset management landscape.

What Is the Investment Thesis for GNOM?

GNOM presents an investment opportunity in the genomics and biotechnology sectors, driven by advancements in genetic research and personalized medicine. With a beta of 1.95, GNOM exhibits higher volatility compared to the broader market. The fund's performance is directly tied to the growth and innovation within the genomics and biotechnology industries. Key value drivers include breakthroughs in gene editing technologies, increasing adoption of personalized medicine, and the overall expansion of the healthcare sector. While GNOM does not offer a dividend yield, potential returns are expected through capital appreciation as the underlying companies in the Solactive Genomics Index grow and innovate. Investors may want to evaluate the risks associated with investing in a specialized sector, including regulatory hurdles, clinical trial failures, and competitive pressures.

Based on FMP financials and quantitative analysis

GNOM Key Highlights

GNOM seeks to replicate the performance of the Solactive Genomics Index, providing targeted exposure to the genomics and biotechnology sectors.

• The fund has a market capitalization of $0.05 billion, indicating its size within the ETF market.
• GNOM's beta of 1.95 suggests higher volatility compared to the overall market, reflecting the dynamic nature of the genomics and biotechnology industries.
• The ETF does not offer a dividend yield, focusing instead on capital appreciation through investments in growth-oriented companies.
• GNOM's investment strategy is centered on companies involved in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements.

Who Are GNOM's Competitors?

GNOM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GNOM's Key Strengths?

Targeted exposure to the high-growth genomics and biotechnology sectors.

• Diversification across multiple companies within the industry.
• Transparent and rules-based investment approach through index tracking.
• Potential for capital appreciation driven by innovation in healthcare.

What Are GNOM's Weaknesses?

High beta of 1.95 indicates higher volatility compared to the broader market.

• Lack of dividend yield may not appeal to income-seeking investors.
• Performance is highly dependent on the success of the genomics and biotechnology sectors.
• Subject to regulatory risks and clinical trial failures within the healthcare industry.

What Are the Key Risks for GNOM?

Regulatory hurdles and clinical trial failures can negatively impact the performance of companies within the genomics and biotechnology sectors.

• Competitive pressures from other thematic ETFs and investment funds.
• Economic downturns and market volatility can impact the value of the ETF's holdings.
• The genomics and biotechnology sectors are subject to rapid technological changes, which can render existing technologies obsolete.
• Ethical concerns surrounding gene editing and genetic engineering may lead to regulatory restrictions and public opposition.

What Are GNOM's Competitive Advantages?

• Specialized Focus: GNOM's focus on genomics and biotechnology provides a unique offering within the ETF market.
• Diversification: The ETF offers diversification across multiple companies within the genomics and biotechnology sectors.
• Index Tracking: GNOM's strategy of tracking the Solactive Genomics Index provides a transparent and rules-based investment approach.
• Thematic Investing: GNOM provides access to a specific investment theme, appealing to investors interested in emerging trends.

What Does GNOM Do?

The Global X Genomics & Biotechnology ETF (GNOM) was created to track the Solactive Genomics Index, offering investors a focused approach to investing in the rapidly evolving fields of genomics and biotechnology. As an exchange-traded fund (ETF), GNOM provides a diversified portfolio of companies that are at the forefront of genetic research, development, and application. This includes firms involved in gene sequencing, gene editing, personalized medicine, and other related biotechnological advancements. GNOM’s strategy is to replicate, before fees and expenses, the price and yield performance of its benchmark index. This allows investors to gain exposure to a basket of stocks representing the genomics and biotechnology sectors without the need to individually select and manage these investments. The fund’s holdings span across various market capitalizations and geographies, providing a broad representation of the genomics and biotechnology landscape. By investing in GNOM, shareholders gain access to companies that are driving innovation in healthcare and potentially transforming the way diseases are diagnosed, treated, and prevented. The ETF is managed by Global X ETFs, a well-known provider of thematic ETFs that focus on emerging trends and disruptive technologies.

What Products and Services Does GNOM Offer?

• Tracks the Solactive Genomics Index.
• Provides exposure to companies involved in genomics and biotechnology.
• Invests in firms involved in gene sequencing and gene editing.
• Offers diversification within the healthcare sector.
• Focuses on companies advancing personalized medicine.
• Replicates the index's performance before fees and expenses.
• Offers investors a way to participate in the growth of genomic technologies.

How Does GNOM Make Money?

• Generates revenue through management fees charged to investors.
• Aims to replicate the performance of the Solactive Genomics Index.
• Offers a diversified portfolio of genomics and biotechnology companies.
• Provides a cost-effective way to invest in a specialized sector.

What Industry Does GNOM Operate In?

GNOM operates within the asset management industry, specifically focusing on thematic ETFs. The genomics and biotechnology sectors are experiencing rapid growth, driven by advancements in genetic research, personalized medicine, and gene editing technologies. The competitive landscape includes other thematic ETFs and investment funds that target the healthcare and biotechnology sectors. GNOM differentiates itself by focusing specifically on genomics, offering investors a targeted approach to capitalize on the growth potential of this specialized area. The increasing demand for innovative healthcare solutions and the growing prevalence of genetic testing are driving the expansion of the genomics market.

Who Are GNOM's Key Customers?

• Individual investors seeking exposure to genomics and biotechnology.
• Institutional investors looking for thematic investment opportunities.
• Financial advisors seeking to diversify client portfolios.
• High-net-worth individuals interested in innovative healthcare technologies.

Insider Activity

12 transactions · 0 purchases, 0 sales, 12 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

GNOM Financials

GNOM Latest News

GNOM Analyst Consensus

GNOM MoonshotScore

Global X - Genomics & Biotechnology ETF Financials Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources